# With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’

> **Open Intelligence Dossier** · First detected: 2026-09-21 18:40 UTC · Category: Business

## Executive Summary
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
"With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.


Outlets currently covering the story include Kalkine Media, GuruFocus, Investor's Business Daily and STAT. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Investing.com South Africa | TD Cowen reiterates Alkermes stock Buy rating on ADHD trial data By Investing.com | [Source Link](https://news.google.com/rss/articles/CBMiwwFBVV95cUxPVUFucDN5VDd2RVlOZDlTRlhGMmh3VDlrMnlBRHRhTFNGV2h0djJTT0pwUkdOWVBTZC1wZlp0NjZBS3FKS2lQOTdLcW1PeTYwYkNvc2VLU2Y0UTRKVDNVQnBkQko2M2VnZ0I1Z2VkODFBanJtbHRFMFVIUWt6X3lXS2xLUmJhamJCV29HNkVLWmxMdUNpU0x6RTNObXRKcEFwQkVKQzRhdlB2NDJidnNCeXJFVEE2MDFET0NUUTdDN0ZDejQ?oc=5) |
| Kalkine Media | Alkermes Announces Positive Phase 1 Topline Results for ALKS 7290 in ADHD Treatment | [Source Link](https://news.google.com/rss/articles/CBMiygFBVV95cUxNRkdMZFVXTVdnOXdtVXEwRHBlVEhtdzEwYlo1NHEyWE1jenNsVGlRalEyaktQSTI5cHFMaHRjalZXY05iSzR5SkJaZE1QajNLRl9vWDRDb2NwUVdrSlo2NERQbUpUQmtEYm50alU0UkhtZFJBSTdMU0U1aXVkN2psaGtibUlDYWxyWDRieDFiMkw5UmNjVFJqemZkWE9OM3lmcFpTMUpESnZGVzFrS2wxaXRKTW9IWUk1QmtZOEJXTmtTLUZwQXVRTWhR?oc=5) |
| GuruFocus | ALKS Reiterates by Needham -- Price Target Maintained at $62.00 | [Source Link](https://news.google.com/rss/articles/CBMingFBVV95cUxPU1dIOWFsa0lrNVY1SU83TDdFRE1VQkdrcEFmb0FTU2QyTFljZ0F4OGtZcU10eFA1R21aUzNoLThOSzhSeEVpSmtqNm92aWxYWGExWmR3a1dqNkpXV1B5SkZfX3FnTTBIRlJCZUJWcTkxT3dYMXE3dEdUeGNrOHE5TlZ2aFVtbWExbXlhbFFuMGdfZFJnWDZHODZsWTNlZw?oc=5) |
| Investor's Business Daily | What This Biotech Learned From Narcolepsy And Took To ADHD | [Source Link](https://news.google.com/rss/articles/CBMihgFBVV95cUxQTU1aWmZTVkJwVWkzQWo2SjhkRnVMOGZYaHVUMUo0dWNGeDBoM0g2eE9tNElUNnBRUzdRRDJrN0pIOXNqT0dIWE5OcEh0SXJNbDFwcGJxcTlvTFV3OGdqRFFiVm5WN1k2QnBfMm1rdmVzWk5BUkhlLVZIMENKWkRFSnpUWTFKQQ?oc=5) |
| STAT | Alkermes’ orexin agonist shows potential to treat ADHD in early-stage trial | [Source Link](https://news.google.com/rss/articles/CBMie0FVX3lxTE15THgzWUluRU5zMG1VNHRnNlQ2ZUI0a0d3NW45MnlHS3VFTHZsRk43SWZlN3hXTW9TMzhvTEVQQWpMUktYcXJZOWd0ekJ2N0NJeHM0YVhUZlZYTUtyTTM2MXpQczhJYzFiNkpJaDA5clNWc3dNRllkWXV2cw?oc=5) |
| Fierce Biotech | With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’ | [Source Link](https://news.google.com/rss/articles/CBMiswFBVV95cUxNNVdxa21hYkdUX1hYdUZnV2ZCbUZQSWlGa3R5OFZhMjhSTF9jMVNrQWZsdDNkclczM3U1NF9sVUR3cXVyeVNhTVRKMHRldUh3Z0xfSUxZM1VIUXI2N1VMWUUxbElqVlYybUcxZXg2WHRiSm9MbndSRmgtNF9NN0ZFRFJpYTd1UXRTQU5xZHZGZ2c3T3VCUENJSG93NWFFSks3SU5UQjJwc3lfXzlnZ1ZOY0RkZw?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-09-21/with-pioneering-adhd-data-alkermes-eyes-orexin-agonist-as-potential-company*